当前位置: 首页 >> 检索结果
共有 7773 条符合本次的查询结果, 用时 2.8210868 秒

661. Declaration of Helsinki's missed opportunity for healthy volunteer trials.

作者: François Bompart.;Jill A Fisher.;Sucheta Banerjee Kurundkar.;François Hirsch.;Shadreck Mwale.
来源: Lancet. 2024年404卷10467期2047-2048页

662. Should WHO partner with TikTok to combat misinformation?

作者: Marco Zenone.;Nora Kenworthy.
来源: Lancet. 2024年404卷10467期2046-2047页

663. North Abyei: the humanitarian and health crisis in Sudan.

作者: Yousif Ali.;Emmanuel Edwar Siddig.;Ayman Ahmed.
来源: Lancet. 2024年404卷10467期2045-2046页

664. The UN World Conjoined Twins Day-a call to global action.

作者: Abdullah A Al Rabeeah.;Ziad A Memish.
来源: Lancet. 2024年404卷10467期2045页

665. Making the invisible visible: using art to explore the facade of objectivity in medicine.

作者: Kerri Davidson.;Robert Rock.;Cyra Levenson.;Anna Reisman.
来源: Lancet. 2024年404卷10467期2042-2043页

666. Offline: Can public health overcome its colonial history?

作者: Richard Horton.
来源: Lancet. 2024年404卷10467期2033页

667. Prostate radiotherapy in the era of intensified systemic treatment of metastatic prostate cancer.

作者: Cristian Udovicich.;Andrew Loblaw.
来源: Lancet. 2024年404卷10467期2023-2026页

668. The next 1000 days: the forgotten ages of child health.

作者: The Lancet.
来源: Lancet. 2024年404卷10467期2021页

669. Temporary blood flow arrest during endovascular thrombectomy for acute ischaemic stroke.

作者: Permesh Singh Dhillon.;Thanh N Nguyen.
来源: Lancet. 2024年404卷10468期2132-2133页

670. Balloon guide catheters for endovascular thrombectomy in patients with acute ischaemic stroke due to large-vessel occlusion in China (PROTECT-MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial.

作者: Jianmin Liu.;Yu Zhou.;Lei Zhang.;Zifu Li.;Wenhuo Chen.;Yueqi Zhu.;Xiaoxi Yao.;Liyong Zhang.;Shen Liu.;Ya Peng.;Ming Wei.;Quanbin Zhang.;Hansheng Shu.;Shouchun Wang.;Wenhua Liu.;Shu Wan.;Tong Li.;Yibin Fang.;Hongxing Han.;Guang Zhang.;Li'an Huang.;Feng Wang.;Guangsen Cheng.;Lianbo Gao.;Hongchao Shi.;Jintao Han.;Yun Luo.;Shuai Li.;Chuwei Cai.;Rong Yin.;Zhenglong Jin.;Chengwei Shao.;Bing Tian.;Yongxin Zhang.;Qiang Li.;Yingying Zhang.;Ping Zhang.;Binben Li.;Pengfei Xing.;Hongjian Shen.;Xuan Zhu.;Xiaoxi Zhang.;Weilong Hua.;Fang Shen.;Meihua Huyan.;Rundong Chen.;Qiao Zuo.;Qiang Li.;Qinghai Huang.;Yi Xu.;Benqiang Deng.;Rui Zhao.;Mayank Goyal.;Yongwei Zhang.;Pengfei Yang.; .
来源: Lancet. 2024年404卷10468期2165-2174页
The effectiveness of using a balloon guide catheter during endovascular thrombectomy in patients with acute ischaemic stroke due to large vessel occlusion of the anterior circulation remains uncertain. We aimed to assess the effectiveness and safety of using a balloon guide catheter during endovascular thrombectomy, compared with using a conventional guide catheter, in this patient population.

671. UNRWA's work is at risk again.

作者: Bassam Abu Hamad.;Zeina Jamaluddine.;Sarah Aly.;Mohammad Salayma.;Yara Asi.;Hani Mowafi.;Francesco Checchi.;Miho Sato.;Asli Bali.;Paul Spiegel.
来源: Lancet. 2024年404卷10468期2157页

672. Drugs for dyslipidaemia: the legacy effect of the Scandinavian Simvastatin Survival Study (4S).

作者: Timo E Strandberg.;Petri T Kovanen.;Donald M Lloyd-Jones.;Frederick J Raal.;Raul D Santos.;Gerald F Watts.
来源: Lancet. 2024年404卷10470期2462-2475页
Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor for atherosclerotic cardiovascular disease. Safe and effective statins remain the cornerstone of therapeutic approach for this indication, including for children with genetic dyslipidaemia, and are one of the most widely prescribed drugs in the world. However, despite the affordability of generic statins, they remain underutilised worldwide. The use of ezetimibe to further decrease plasma LDL cholesterol and the targeting of other atherogenic lipoproteins, such as triglyceride-rich lipoproteins and lipoprotein(a), are likely to be required to further reduce atherosclerotic cardiovascular disease events. Drugs directed at these lipoproteins, including gene silencing and editing methods that durably suppress the production of proteins, such as PCSK9 and ANGPTL3, open novel therapeutic options to further reduce the development of atherosclerotic cardiovascular disease.

673. The cost of not investing in the next 1000 days: implications for policy and practice.

作者: Milagros Nores.;Claudia Vazquez.;Emily Gustafsson-Wright.;Sarah Osborne.;Jorge Cuartas.;Mark J Lambiris.;Dana C McCoy.;Florencia Lopez-Boo.;Jere Behrman.;Raquel Bernal.;Catherine E Draper.;Anthony D Okely.;Mark S Tremblay.;Aisha K Yousafzai.;Joan Lombardi.;Günther Fink.
来源: Lancet. 2024年404卷10467期2117-2130页
Building on the evidence from the first paper in this Series highlighting the fundamental importance of healthy and nurturing environments for children's growth and development in the next 1000 days (ages 2-5 years), this paper summarises the benefits and costs of key strategies to support children's development in this age range. The next 1000 days build on the family-based and health-sector based interventions provided in the first 1000 days and require broader multisectoral programming. Interventions that have been shown to be particularly effective in this age range are the provision of early childhood care and education (ECCE), parenting interventions, and cash transfers. We show that a minimum package of 1 year of ECCE for all children would cost on average less than 0·15% of low-income and middle-income countries' current gross domestic product. The societal cost of not implementing this package at a national and global level (ie, the cost of inaction) is large, with an estimated forgone benefit of 8-19 times the cost of investing in ECCE. We discuss implications of the overall evidence presented in this Series for policy and practice, highlighting the potential of ECCE programming in the next 1000 days as an intervention itself, as well as a platform to deliver developmental screening, growth monitoring, and additional locally required interventions. Providing nurturing care during this period is crucial for maintaining and further boosting children's progress in the first 1000 days, and to allow children to reach optimal developmental trajectories from a socioecological life-course perspective.

674. The next 1000 days: building on early investments for the health and development of young children.

作者: Catherine E Draper.;Aisha K Yousafzai.;Dana C McCoy.;Jorge Cuartas.;Jelena Obradović.;Sunil Bhopal.;Jane Fisher.;Joshua Jeong.;Sonja Klingberg.;Kate Milner.;Lauren Pisani.;Aditi Roy.;Jonathan Seiden.;Christopher R Sudfeld.;Stephanie V Wrottesley.;Günther Fink.;Milagros Nores.;Mark S Tremblay.;Anthony D Okely.
来源: Lancet. 2024年404卷10467期2094-2116页
Following the first 1000 days of life that span from conception to two years of age, the next 1000 days of a child's life from 2-5 years of age offer a window of opportunity to promote nurturing and caring environments, establish healthy behaviours, and build on early gains to sustain or improve trajectories of healthy development. This Series paper, the first of a two-paper Series on early childhood development and the next 1000 days, focuses on the transition to the next 1000 days of the life course, describes why this developmental period matters, identifies the environments of care, risks, and protective factors that shape children's development, estimates the number of children who receive adequate nurturing care, and examines whether current interventions are meeting children's needs. Paper 2 focuses on the cost of inaction and the implications of not investing in the next 1000 days. In low-income and middle-income countries (LMICs), only 62 million children aged 3 and 4 years (25·4%) currently receive adequate nurturing care during the next 1000 days, leaving 181·9 million children exposed to risks that jeopardise their healthy development. Inputs across nurturing care dimensions of health, nutrition, protection, responsive care, and learning vary substantially across countries. In LMICs, although 86·2% of children have a healthy weight in this period, less than one in three children have access to developmental stimulation or are protected from physical punishment, and only 38·8% have access to early childhood care and education services. Intervention research in LMICs in the next 1000 days is scarce. The continuity of developmentally appropriate nurturing care, coordination across health, education, and protection sectors, and the implementation of interventions to support caregivers and improve the quality of education and care remain top priorities in this period. These sectors play key roles in promoting quality early care and education for this age group, which will help maximise developmental potential and opportunities of children globally and help progress towards the achievement of the Sustainable Development Goals.

675. The first and next 1000 days: a continuum for child development in early life.

作者: Victor M Aguayo.;Pia R Britto.
来源: Lancet. 2024年404卷10467期2028-2030页

676. Amyloid-lowering treatment in Alzheimer's disease.

作者: Frank Jessen.;Lutz Frölich.;Jakub Hort.;Bengt Winblad.;Juan Fortea.
来源: Lancet. 2024年404卷10468期2161-2162页

677. The obesity crisis in the USA: why are there no signs of plateauing yet?

作者: Sylvain Sebert.
来源: Lancet. 2024年404卷10469期2241-2242页

678. National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990-2021, and forecasts up to 2050.

作者: .
来源: Lancet. 2024年404卷10469期2278-2298页
Over the past several decades, the overweight and obesity epidemic in the USA has resulted in a significant health and economic burden. Understanding current trends and future trajectories at both national and state levels is crucial for assessing the success of existing interventions and informing future health policy changes. We estimated the prevalence of overweight and obesity from 1990 to 2021 with forecasts to 2050 for children and adolescents (aged 5-24 years) and adults (aged ≥25 years) at the national level. Additionally, we derived state-specific estimates and projections for older adolescents (aged 15-24 years) and adults for all 50 states and Washington, DC.

679. Divisions over the regulation of lecanemab.

作者: Bart De Strooper.;Christian Haass.;John Hardy.;Henrik Zetterberg.
来源: Lancet. 2024年404卷10468期2160-2161页

680. Thomas Killip III.

作者: Geoff Watts.
来源: Lancet. 2024年404卷10466期1920页
共有 7773 条符合本次的查询结果, 用时 2.8210868 秒